1 / 34

Triple Negative Breast Cancer

Triple Negative Breast Cancer. Lazzaro Repetto ASL 1 Imperiese Ospedale G. Borea - Sanremo. Clinical Aspects and Biology of TNBC. TIL. necrosis. Cell sheets. TIL. Pushing tumor. ER 0. Atypia & mitosis. ER 0. ER+ in normal tissue. EGFR. W Fooulkes , NEJM 2010. CK-5.

miach
Download Presentation

Triple Negative Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Triple Negative Breast Cancer Lazzaro Repetto ASL 1 Imperiese Ospedale G. Borea - Sanremo

  2. ClinicalAspects and Biology of TNBC

  3. TIL necrosis Cellsheets TIL Pushingtumor • ER 0 Atypia & mitosis ER 0 ER+ in normaltissue EGFR W Fooulkes, NEJM 2010 CK-5

  4. [TITLE]

  5. …….and Heterogeneity of Basal Like! A Prat & CMPerou, Molecular Oncology 2011

  6. [TITLE]

  7. The link to BRCA1

  8. [TITLE] BRCA1 Related Breast Cancer

  9. [TITLE]

  10. [TITLE]

  11. [TITLE]

  12. Prognosis and Traditional CT

  13. [TITLE]

  14. [TITLE]

  15. [TITLE]

  16. [TITLE]

  17. New TheraputicApproaches

  18. [TITLE]

  19. Platinum

  20. IniparibPhase II NEJM 2011

  21. ….andIniparibPhase III [TITLE] ASCO 2011

  22. [TITLE] ASCO 2011

  23. [TITLE] ASCO 2011

  24. [TITLE] ASCO 2011

  25. [TITLE] ASCO 2011

  26. [TITLE] ASCO 2011

  27. [TITLE]

  28. [TITLE]

  29. [TITLE]

  30. [TITLE]

  31. [TITLE]

  32. [TITLE]

  33. Conclusions

  34. TNBCs are heterogeneous • BLBCs are heterogeneous • BRCA1 carrierscancers are heterogeneous • Conventional CT appropriated • CT + Bevacizumabshould be consideredas an option in MBC? • Platinum, Cetuximab, PARPi in the future

More Related